Raiffeisen Bank International AG Acquires 16,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Key Points

• Raiffeisen Bank International AG has dramatically increased its stake in Sarepta Therapeutics by purchasing 16,000 shares, resulting in a total of 17,465 shares valued at approximately $1.22 million.
• Despite record revenue growth of 80.2% year-over-year, Sarepta reported a significant earnings miss with a loss per share of ($3.42) against expectations of $2.20, highlighting ongoing financial challenges.
• Analysts rate Sarepta Therapeutics stock predominantly as a "Hold," with a consensus price target of $49.12, amidst a backdrop of various recent downgrades and mixed analyst opinions.

Raiffeisen Bank International AG grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1,092.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,465 shares of the biotechnology company's stock after purchasing an additional 16,000 shares during the period. Raiffeisen Bank International AG's holdings in Sarepta Therapeutics were worth $1,220,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Blueshift Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at $488,000. Sound View Wealth Advisors Group LLC increased its position in Sarepta Therapeutics by 18.8% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 4,863 shares of the biotechnology company's stock worth $310,000 after purchasing an additional 771 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at approximately $1,458,000. Hurley Capital LLC grew its position in Sarepta Therapeutics by 139.2% in the first quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company's stock worth $92,000 after acquiring an additional 835 shares in the last quarter. Finally, Maridea Wealth Management LLC lifted its stake in shares of Sarepta Therapeutics by 101.8% in the 1st quarter. Maridea Wealth Management LLC now owns 9,147 shares of the biotechnology company's stock valued at $584,000 after purchasing an additional 4,614 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Down 2.9%

SRPT traded down $0.49 during trading on Wednesday, reaching $16.26. 13,196,204 shares of the company's stock were exchanged, compared to its average volume of 21,530,484. The company's fifty day moving average price is $22.95 and its 200-day moving average price is $58.99. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. The firm has a market capitalization of $1.60 billion, a PE ratio of -6.04 and a beta of 0.46. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $145.00.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. Sarepta Therapeutics's quarterly revenue was up 80.2% on a year-over-year basis. During the same quarter last year, the business posted $0.73 EPS. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several analyst reports. Scotiabank upgraded Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price target on the stock in a report on Friday, June 6th. Guggenheim decreased their target price on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reissued a "sell" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. Oppenheimer upgraded shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $30.00 to $37.00 in a research report on Tuesday, July 29th. Finally, Sanford C. Bernstein assumed coverage on Sarepta Therapeutics in a report on Tuesday, July 29th. They issued a "market perform" rating and a $13.00 price target for the company. Six analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $49.12.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.